Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate (GPB) for the Treatment of Hepatic Encephalopathy in Hepatology

[GlobeNewswire] – BRISBANE, Calif. — Hyperion Therapeutics, Inc. today announced that results of the Phase 2 trial of glycerol phenylbutyrate (GPB) for the treatment of hepatic encephalopathy (HE) were published in the … more

View todays social media effects on HPTX

View the latest stocks trending across Twitter. Click to view dashboard

See who Hyperion is hiring next, click here to view